Conditional European approval for Fampyra for MS walking disability
This article was originally published in Scrip
Executive Summary
Following a reluctant recommendation by the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) in May, the European Commission has now conditionally approved Biogen Idec and Acorda Therapeutics' Fampyra (sustained-release fampridine), to improve walking in adult patients with multiple sclerosis (MS) who have walking disability.